N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19) and can be associated with serious complications, including acute respiratory distress syndrome. This condition is accompanied by a massive release of cytokines, also denominated cytokin...
Saved in:
Main Authors: | José Luis Izquierdo-Alonso (Author), Sandra Pérez-Rial (Author), Carolina Gotera Rivera (Author), Germán Peces-Barba (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence
by: Wong KK, et al.
Published: (2021) -
N-Acetylcysteine to Combat COVID-19: An Evidence Review
by: Shi Z, et al.
Published: (2020) -
N-Acetylcysteine, N-Acetylcysteine Amide, and Thioredoxin Mimetic Peptides Regenerate Mercaptoalbumin and Exhibit Antioxidant Activity
by: Sonia Eligini, et al.
Published: (2024) -
Tele-Audiology: Current State and Future Directions
by: Kristen L. D'Onofrio, et al.
Published: (2022) -
N-Acetylcysteine and Atherosclerosis: Promises and Challenges
by: Yuqi Cui, et al.
Published: (2023)